Summary
Here's Why You Should Add ARQT Stock to Your Portfolio Now
Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
Arcutis Biotherapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 565 | $9,785.28 | $16,204.2 | $6,418.92 | 65.6% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 28,900 | $751,846.02 | $758,047 | $6,200.98 | 0.82% |
| LN Louis Navellier NAVELLIER & ASSOCIATES Inc. | 19,696 | $483,055.36 | $512,686.9 | $29,631.54 | 6.13% |
| NA Nizar Araji National Bank Of Canada /FI/ | 12 | $321.12 | $303.48 | -$17.64 | -5.49% |
| BG Bart Gancher Intech Investment Management LLC | 26,209 | $383,036.2 | $662,825.61 | $279,789.41 | 73.05% |
Arcutis Biotherapeutics Inc. (ARQT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arcutis Biotherapeutics Inc. ever had a stock split?
Arcutis Biotherapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Todd Franklin Watanabe CEO | NASDAQ (NGS) Exchange | 03969K108 CUSIP |
| US Country | 354 Employees | - Last Dividend | - Last Split | 31 Jan 2020 IPO Date |
Overview
Arcutis Biotherapeutics, Inc. is a pioneering biopharmaceutical enterprise dedicated to advancing and bringing to market treatments for various dermatological conditions. The company carved out its niche in the healthcare and pharmaceutical landscape by focusing on innovations in dermatology, aiming to address unmet medical needs. Initially known as Arcutis, Inc., the company underwent a rebranding in October 2019, emerging as Arcutis Biotherapeutics, Inc., to perhaps more accurately reflect its focus and ambition in the biotherapeutic domain. Since its inception in 2016, Arcutis has positioned its headquarters in Westlake Village, California, evolving its portfolio to target a variety of skin conditions with considerable unmet medical need.
Products and Services
- ARQ-151 (topical roflumilast cream)
ARQ-151 is Arcutis Biotherapeutics' leading product candidate, designed as a topical cream with the active ingredient roflumilast. It has successfully completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. Its development reflects the company’s commitment to providing innovative solutions for dermatological conditions with significant patient impact.
- ARQ-154 (topical ZORYVE)
This is another promising product from Arcutis, formulated to combat scalp and body psoriasis as well as seborrheic dermatitis. Its development underscores the company's dedication to expanding its portfolio to include treatments for widespread dermatological conditions that affect large populations globally.
- ARQ-252 (selective topical janus kinase type 1 inhibitor)
Arcutis is developing ARQ-252 as a targeted therapeutic approach for conditions like hand eczema and vitiligo. By focusing on the inhibition of janus kinase type 1, this product aims to offer a novel mechanism of action for treating these challenging dermatological conditions.
- ARQ-255 (topical JAK1 inhibitor for alopecia areata)
With ARQ-255, the company targets alopecia areata, an autoimmune condition causing hair loss. This product's development highlights Arcutis Biotherapeutics' efforts in addressing the need for more effective treatments for conditions that can significantly affect patients' quality of life and self-esteem.
- ARQ-234 (CD200R fusion protein for moderate-to-severe atopic dermatitis)
The development of ARQ-234, a CD200R fusion protein for treating moderate-to-severe atopic dermatitis, epitomizes the innovative spirit of Arcutis Biotherapeutics. This product is aimed at providing a new option for patients struggling with severe forms of this common skin condition, potentially improving outcomes and quality of life for this patient population.
